Background Deficiency of the natural antagonist of interleukin-1 was first described in 2009 and so far 20 patients has been reported. In Brazil just two cases have been reported both carrying the same homozygous 15 bp deletion.
Leonardo Oliveira Mendonça +9 more
doaj +1 more source
Rilonacept pharmacokinetics in children with systemic juvenile idiopathic arthritis [PDF]
Systemic juvenile idiopathic arthritis (sJIA) is a disease characterized by arthritis in children
Julie Autmizguine +3 more
openaire +2 more sources
Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From the RHAPSODY Long-term Extension. [PDF]
BACKGROUND: Rilonacept inhibits the interleukin-1 pathway, and extended treatment in patients with recurrent pericarditis (RP) reduced recurrence risk by 98% in the phase 3 trial, RHAPSODY long-term extension (LTE).
Klutstein, Marc +16 more
core +3 more sources
Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis [PDF]
OBJECTIVE: To assess the efficacy and safety of rilonacept, an interleukin-1 inhibitor, in a randomized, double-blind, placebo-controlled trial. METHODS: An initial 4-week double-blind placebo phase was incorporated into a 24-week randomized multicenter ...
Spalding, S. J. +10 more
core +1 more source
Objective The objective of this study was to characterize the clinical, immunologic, and synovial tissue features of a patient with a systemic juvenile idiopathic arthritis (sJIA) who carries a novel heterozygous STAT5B loss‐of‐function variant (p.Gln139Ter) and whose arthritis responded markedly to interleukin‐17A (IL‐17A) inhibition.
Indira Sriram +14 more
wiley +1 more source
Successful Treatment of Recurrent Pericarditis With Rilonacept in Acute Promyelocytic Leukemia
A 40-year-old woman presented with recurrent pericarditis and pericardial effusion while receiving treatment with all-trans retinoic acid and arsenic trioxide for recently diagnosed acute promyelocytic leukemia. She was successfully treated with the interleukin-1 inhibitor rilonacept after experiencing multiple recurrences with triple therapy with ...
Mustafa Atar +9 more
openaire +2 more sources
Neutrophils: Heterogeneity, Biology, Diseases, and Therapeutic Strategies
Neutrophils exhibit remarkable functional plasticity and play dual roles in tissue protection and disease progression. This review summarizes their key biological functions and highlights the shift from conventional broad‐spectrum interventions to neutrophil‐based drug delivery systems.
Yibing Zhang +4 more
wiley +1 more source
The aging of the human body is a complex process driven by multiple contributing factors. Based on their underlying mechanisms, current anti‐aging interventions can be classified into six primary categories. This paper summarizes the most promising anti‐aging strategies within each class. ABSTRACT The global prevalence of aging and age‐related diseases
Feifei Li +4 more
wiley +1 more source
Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator [PDF]
Introduction In phase-3 clinical trials, the interleukin (IL-1) blocker, rilonacept (IL-1 Trap), demonstrated efficacy for gout flare prevention during initiation of urate-lowering therapy.
Robert A Terkeltaub +15 more
core +1 more source
Metabolic Regulation of Macrophages in Health and Disease
Extracellular metabolites drive metabolic rewiring of glucose, lipid, and amino acid pathways in macrophages, steering their polarization toward pro‐ or anti‐inflammatory phenotypes and shaping a wide range of disease processes. Macrophages from different tissues display distinct metabolic signatures, and therapeutic strategies that target these ...
Shan Huang +6 more
wiley +1 more source

